Fusion Antibodies Management

Management criteria checks 1/4

Fusion Antibodies' CEO is Adrian Kinkaid, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is £183.49K, comprised of 60.5% salary and 39.5% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth £8.05K. The average tenure of the management team and the board of directors is 1.8 years and 2.3 years respectively.

Key information

Adrian Kinkaid

Chief executive officer

UK£183.5k

Total compensation

CEO salary percentage60.5%
CEO tenure1.8yrs
CEO ownership0.3%
Management average tenure1.8yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Aug 31
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

Jan 25
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

May 09
We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Mar 17
Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Jan 04
Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

CEO Compensation Analysis

How has Adrian Kinkaid's remuneration changed compared to Fusion Antibodies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-UK£3m

Jun 30 2023n/an/a

-UK£3m

Mar 31 2023UK£183kUK£111k

-UK£3m

Compensation vs Market: Adrian's total compensation ($USD229.25K) is below average for companies of similar size in the UK market ($USD344.28K).

Compensation vs Earnings: Insufficient data to compare Adrian's compensation with company performance.


CEO

Adrian Kinkaid (56 yo)

1.8yrs

Tenure

UK£183,490

Compensation

Dr. Adrian Robert Kinkaid, Ph D., serves as Chief Executive Officer of Fusion Antibodies plc since August 15, 2022. and serves as its Director since August 25, 2022.He serves as Chief Executive Officer of...


Leadership Team

NamePositionTenureCompensationOwnership
Adrian Kinkaid
CEO & Director1.8yrsUK£183.49k0.26%
£ 8.1k
Richard Buick
Chief Scientific Officer & Director3.3yrsUK£127.00k0.73%
£ 22.9k
Jim Johnston
Founderno datano datano data
Stephen Smyth
Company Secretaryless than a yearno datano data
Nicola Hamilton
Operations Managerless than a yearno datano data
Paul Kerr
Consultant3.3yrsUK£180.39kno data

1.8yrs

Average Tenure

49.5yo

Average Age

Experienced Management: FAB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Adrian Kinkaid
CEO & Director1.8yrsUK£183.49k0.26%
£ 8.1k
Richard Buick
Chief Scientific Officer & Director12.7yrsUK£127.00k0.73%
£ 22.9k
Stephen Smyth
Company Secretaryless than a yearno datano data
Simon Douglas
Non-Executive Chairman12.7yrsUK£30.00k0.58%
£ 18.2k
Colin Walsh
Non-Executive Director17.3yrsUK£27.00k0.63%
£ 19.7k
Terence Rabbitts
Member of Scientific Advisory Panel2.3yrsno datano data
Matthew Baker
Member of Scientific Advisory Panel & Independent Non-Executive Director2.3yrsUK£30.00kno data
Charlotte Deane
Member of Scientific Advisory Panel2.3yrsno datano data

2.3yrs

Average Tenure

54.5yo

Average Age

Experienced Board: FAB's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.